Phase 2 Startnegative~month

Phase 2 Start: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind

April 1, 2027

Company: COLLEGIUM PHARMACEUTICAL, INC (COLL)
Drug: psilocybin
Indication: Opioid Use Disorder

Other upcoming events for COLL

Phase 3 ReadoutPhase 3 Topline: Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

Patent ExpiryPatent/Exclusivity Expiry: TROXYCA ER

Patent ExpiryPatent/Exclusivity Expiry: VIVITROL

Patent ExpiryPatent/Exclusivity Expiry: EMBEDA

Patent ExpiryPatent/Exclusivity Expiry: QUILLIVANT XR

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 2 Start: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind — COLL Phase 2 Start | BioSniper